MannKind Corporation (FRA:NNFN)

Germany flag Germany · Delayed Price · Currency is EUR
4.584
+0.012 (0.26%)
At close: Nov 28, 2025
-26.33%
Market Cap1.42B
Revenue (ttm)267.44M
Net Income (ttm)24.92M
Shares Outn/a
EPS (ttm)0.08
PE Ratio56.86
Forward PE27.77
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume148
Open4.584
Previous Close4.572
Day's Range4.584 - 4.584
52-Week Range2.925 - 6.700
Betan/a
RSI52.17
Earnings DateFeb 23, 2026

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipelin... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1991
Employees 407
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol NNFN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.